行情

ADMP

ADMP

Adamis制药
NASDAQ

实时行情|Nasdaq Last Sale

0.6964
-0.0339
-4.64%
盘后: 0.7320 +0.0356 +5.11% 17:43 01/24 EST
开盘
0.7150
昨收
0.7303
最高
0.7470
最低
0.6834
成交量
45.25万
成交额
--
52周最高
3.290
52周最低
0.4800
市值
4,292.18万
市盈率(TTM)
-0.9344
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADMP 新闻

  • Adamis Pharmaceuticals Sees Prelim. Q4 Product Sales $16.3M, FY19 Product Sales $54.6M
  • Benzinga.01/08 14:19
  • Edited Transcript of ADMP earnings conference call or presentation 12-Nov-19 10:00pm GMT
  • Thomson Reuters StreetEvents.01/03 20:57
  • Adamis Pharmaceuticals Corporation (ADMP): Are Hedge Funds Right About This Stock?
  • Insider Monkey.2019/12/23 20:59
  • Adamis Pharma Offers Update On ZIMHI New Drug Application Resubmission Process: Co. Sent Responses To FDA Related To Complete Response Letter, Requested Type-A Meeting, Is Currently Awaiting Response From FDA
  • Benzinga.2019/12/19 14:05

更多

所属板块

制药
-1.84%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

ADMP 简况

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
展开

Webull提供Adamis Pharmaceuticals Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。